Business Context and Reporting Period
This Form 8-K Current Report was filed by Palisade Bio, Inc. on February 8, 2023, covering events occurring on February 2, 2023, and February 6, 2023. The company is a biotechnology firm incorporated in Delaware with its principal executive offices in Carlsbad, California.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses on corporate governance, executive appointments, and equity compensation grants.
Material Changes and Corporate Actions
Executive Appointments and Board Changes
- Chief Operating Officer: Robert McRae was appointed as Chief Operating Officer effective February 2, 2023. He previously served as SVP of Operations and Strategic Development since December 2021.
- Board Appointment: J.D. Finley, the Company's CFO and interim CEO, was appointed to the Board of Directors on February 2, 2023, expanding the board from seven to eight members.
Compensation Adjustments
- Robert McRae: Base salary set at $400,000 per annum with a target bonus of 40%.
- J.D. Finley: Base salary increased from $440,000 to $490,000, and target bonus increased to 45% of base salary. These changes were effective October 1, 2022.
Unregistered Sales of Equity Securities
On February 6, 2023, the Company issued conditional equity awards to certain officers and senior management, subject to shareholder approval under Nasdaq Rule 5635. If approval is not obtained, the awards may be unwound.
- Options: 81,500 options issued with an exercise price of $2.40 per share (closing price on grant date). Vesting occurs quarterly over three years. Aggregate grant date value: $125,175.
- Restricted Stock Units (RSUs): 59,500 RSUs issued. Vesting occurs quarterly over three years. Aggregate grant date value: $142,800.
- Performance Restricted Stock Units (PSUs): 68,700 PSUs issued. Vesting is contingent on stock price milestones: 50% at a 20-day VWAP of $3.20 and 50% at a 20-day VWAP of $4.25. Aggregate grant date value: $164,880.
Guidance, Outlook, and Risks
The filing does not provide financial guidance or outlook. The primary contingency noted is the requirement for shareholder approval to validate the February 6, 2023, equity awards; without this approval, the grants are subject to cancellation.
Key Facts for Investor Verification
- Verify the outcome of the shareholder vote required to approve the $432,855 in total equity awards granted on February 6, 2023.
- Confirm the execution of formal employment agreements for Robert McRae and the amendment to J.D. Finley's agreement to reflect the salary and bonus increases.
- Monitor the performance conditions for the PSUs, specifically the stock price thresholds of $3.20 and $4.25 required for vesting.
- Note the expansion of the Board of Directors to eight members following J.D. Finley's appointment.